Research

The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation

Nalan Kayhan1*, Benjamin Funke2*, Lars Oliver Conzelmann1, Harald Winkler2, Stefan Hofer2, Jochen Steppan2, Heinfried Schmidt^, Hubert Bardenheuer2, Christian-Friedrich Vahl1 and Markus A Weigand2,3

1Department of Thoracic and Cardiovascular Surgery, University of Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
2Department of Anesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
3Department of Anesthesiology and surgical Intensive Care Medicine, University hospital of Gießen and Marburg, Campus Gießen, Rudolf-Buchheim Strasse 7, 35292 Gießen, Germany

* Contributed equally  ^ Deceased

Corresponding author: Markus A Weigand, markus.weigand@med.uni-heidelberg.de

Received: 8 May 2008 Revisions requested: 21 May 2008 Revisions received: 10 Sep 2008 Accepted: 13 Oct 2008 Published: 13 Oct 2008

Critical Care 2008, 12:R125 (doi:10.1186/cc7033)
This article is online at: http://ccforum.com/content/12/5/R125
© 2008 Kayhan et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction The treatment of septic conditions in critically ill patients is still one of medicine’s major challenges. Cyclic nucleotides, adenosine and its receptors play a pivotal role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction. The aim of this study was to verify the hypothesis that adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibition by erythro-9-[2-hydroxyl-3-nonyl]-adenine could be beneficial in experimental endotoxicosis/sepsis.

Method We used two established animal models for endotoxicosis and sepsis. Twenty-four male Wistar rats that had been given intravenous endotoxin (Escherichia coli lipopolysaccharide) were treated with either erythro-9-[2-hydroxyl-3-nonyl]-adenine infusion or 0.9% saline during a study length of 120 minutes. Sepsis in 84 female C57BL/6 mice was induced by caecal ligation and puncture. Animals were treated with repeated erythro-9-[2-hydroxyl-3-nonyl]-adenine injections after 0, 12 and 24 hours or 4, 12 and 24 hours for delayed treatment.

Results In endotoxaemic rats, intestinal production of hypoxanthine increased from 9.8 +/- 90.2 μmol/l at baseline to 411.4 +/- 124.6 μmol/l and uric acid formation increased from 1.5 +/- 2.3 mmol/l to 13.1 +/- 2.7 mmol/l after 120 minutes. In endotoxaemic animals treated with erythro-9-[2-hydroxyl-3-nonyl]-adenine, we found no elevation of adenosine metabolites. The lactulose/L-rhamnose ratio (14.3 versus 4.2 in control animals; p = 2.5 x 10^-7) reflects a highly permeable small intestine and through the application of erythro-9-[2-hydroxyl-3-nonyl]-adenine, intestinal permeability could be re-established. The lipopolysaccharide animals had decreased L-rhamnose/3-O-methyl-D-glucose urine excretion ratios. Erythro-9-[2-hydroxyl-3-nonyl]-adenine reduced this effect. The mucosa damage score of the septic animals was higher compared with control and therapy animals (p < 0.05). Septic shock induction by caecal ligation and puncture resulted in a 160-hour survival rate of about 25%. In contrast, direct adenosine deaminase-1 inhibition resulted in a survival rate of about 75% (p = 0.0018). A protective effect was still present when erythro-9-[2-hydroxyl-3-nonyl]-adenine treatment was delayed for four hours (55%, p = 0.029).

Conclusions We present further evidence of the beneficial effects achieved by administering erythro-9-[2-hydroxyl-3-nonyl]-adenine, an adenosine deaminase-1 and cyclic guanosine monophosphate-stimulated phosphodiesterase inhibitor, in an endotoxicosis and sepsis animal model. This suggests a potential therapeutic option in the treatment of septic conditions.

ADA: adenosine deaminase; ANOVA: analysis of variance; APACHE: Acute Physiology and Chronic Health Evaluation; CLP: caecal ligation and puncture; EHNA: erythro-9-[2-hydroxyl-3-nonyl]-adenine; HPLC: high-performance liquid chromatography; K2HPO4: dipotassium phosphate; KH2PO4: potassium dihydrogen phosphate; LPS: lipopolysaccharide; NaCl: sodium chloride; PDE2: guanosine monophosphate-stimulated phosphodiesterase; SCID: severe combined immunodeficiency disease; SEM: standard error of the mean.
Introduction

Despite improvements in treatment modalities, the leading cause of death in non-coronary intensive care unit patients remains sepsis and septic shock, complex systemic activations of inflammation and coagulation in response to an infectious insult [1,2].

The purine nucleoside adenosine, a plurifunctional mediator and modulator of myriad physiological processes, which also serves as the substrate for ATP, is elevated at injured and inflamed sites, as well as in the plasma of septic and septic shock patients [3]. It is becoming increasingly apparent that this molecule and its receptors that elevate levels of cAMP, play a crucial role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction [4-7]. By signalling through its specific Gs protein-coupled A2A adenosine receptor, adenosine suppresses the immune system, primarily by inhibiting lymphoid or myeloid cells [5,8] including neutrophils [9], macrophages [10], lymphocytes [11,12] and platelets [13]. A2A receptor-knockout mice present a phenotype of enhanced tissue damage and inflammation [5,14]. Furthermore, adenosine is an endogenous inhibitor of neutrophil-induced endothelial cell injury [15,16] and β2-integrin expression on polymorphonuclear leucocytes, which mediate adhesion to the vascular endothelium, is mainly modulated by A2A receptors [17].

Inhibition of rephosphorylation of adenosine by adenosine kinase inhibitors [18] or its degradation by adenosine deaminase (ADA) improves survival of sepsis in various sepsis models [19-21]. ADA is an enzyme that is involved in purine metabolism and essential for the proliferation, maturation and function of lymphoid cells. Congenital deficiency of this enzyme is associated with an accumulation of deoxyadenosine triphosphates that will inhibit the activity of ribonucleotide diphosphate reductase. This results in severe combined immunodeficiency disease (SCID).

ADA activity is composed of two isoenzymes, referred to as ADA1 and ADA2 [22]. ADA1 is ubiquitous and highly efficient in deaminating the substrates adenosine and 2’deoxyadenosine. The isoenzyme ADA2 coexists with ADA1 only in monocytes and macrophages [23]. Law and colleagues demonstrated the beneficial effect of 2’deoxycoformycin (pentostatin), an exclusive ADA2 inhibitor, in preventing the systemic inflammatory response syndrome secondary to faecal peritonitis in rats [24]. There is a lack of data concerning the question if a specific inhibitor of ADA1 could also influence survival rates in septic conditions.

Another critical aspect of a septic condition is its intestinal barrier dysfunction resulting in bacterial translocation and thereby perpetuating and aggravating the syndrome [25,26]. Endothelial hyperpermeability which results in a vascular leakage can induce edema formation in the intestinal mucosa. This might contribute to increased gut permeability. Suttrop and Seybold identified the importance of cyclic guanosine monophosphate-stimulated phosphodiesterase-2 (PDE2) for the integrity of endothelial barrier function [27,28]. They presented evidence that in severe infection, high PDE2 activity may contribute to endothelial barrier dysfunction, which can be antagonised by PDE2 inhibition [28].

In this study we used an endotoxicosis animal model and a sepsis animal model to provide evidence of the beneficial effects of administration of erythro-9-[2-hydroxy-3-nonyl] adenine (EHNA), a specific ADA1 and PDE2 inhibitor, on the production of adenosine metabolites and intestinal permeability, and improved survival rates.

Materials and methods

All experiments were performed in accordance with the guidelines for research with experimental animals (Helsinki Declaration) and were approved by the Governmental Animal Protection Committee (Karlsruhe, Germany).

Endotoxaemic challenge

Male Wistar rats (250 g to 330 g body weight) were kept on a diet of standard rat food until the day before the experiment. Eight hours before the experiment began, food was withheld from all animals but free access to water was maintained. The rats were anaesthetised intraperitoneally with 60 mg/kg sodium pentobarbital (Nembutal, Sanofi-aventis, Duesseldorf, Germany). The right internal jugular vein, the left femoral vein and the left femoral artery were cannulated with polyethylene tubings (outer diameter = 0.9 mm; inner diameter = 0.5 mm) to measure mean arterial pressure, and to allow drug infusion and blood sampling, respectively. For blood sampling from the portal vein, a midline laparotomy was performed, the small intestine was carefully displaced and the portal vein was punctured proximal to the splenic vein at three different times. After each blood collection from the portal vein, the intestine was covered with warmed (37°C) saline-soaked gauze to preserve moistness and temperature. Rectal temperature was measured using a thermistor probe (YSI-400 Series) and maintained at 37°C with the help of a heating ventilator.

Rats were randomised into three groups of eight animals each (Figure 1). After the animals were prepared, they were allowed a 30-minute stabilisation period. Endotoxaemia was induced immediately after the baseline measurements by continuous intravenous infusion of 1.5 mg/kg/hour endotoxin (lipopolysaccharide (LPS) from Escherichia coli 026:B6; Sigma Chemicals, Deisenhofen, Germany) diluted in sodium chloride (NaCl) 0.9% for 60 minutes. The animals of group B (LPS + EHNA) additionally received a continuous intravenous infusion of 5 mg/kg/hour EHNA diluted in NaCl 0.9% for 60 minutes from the beginning of the endotoxaemic challenge. Animals of the control group received no EHNA or endotoxin. The same
amount of fluids was infused in all rats for the total duration of the study (120 minute).

**Analysis of purine compounds**

Purine compounds (hypoxanthine and uric acid) were measured in 0.2 ml of collected blood in precooled dipyridamole solution (0.2 ml; 5 x 10^-5 M) to prevent nucleoside uptake by red blood cells. After immediate centrifugation at 4°C, plasma supernatant (0.3 ml) was deproteinized with perchloric acid (70%; 0.05 ml). After neutralisation with potassium dihydrogen phosphate (KH2PO4) and centrifugation, nucleosides were determined by HPLC. We automatically injected 0.1 ml samples onto a C-18 column (Nova-Pak C18, 3.9 mm x 150 mm, Waters Instruments, Rochester, NY). The linear gradient started at 100% KH2PO4/K2HPO4 (1:1 mixture of mono and dipotassium phosphate) 1:1 (0.1 M; pH 4.0) and increased to 60% of 60/40 methanol/water (v/v) in 15 minutes, the flow rate being 1.0 ml/minute. This was followed by a reversal of the gradient to initial conditions over the next three minutes. We continuously monitored absorbance of the column eluate by using a photodiode array detector (Waters 996) to measure hypoxanthine at 254 nm and uric acid at 293 nm. We performed peak identification and quantitation of the respective compounds by comparing the retention times of the sample peaks with respective peaks of ultrapure standards.

**Measurements**

Mean arterial blood pressure and temperature were recorded at baseline and at 15, 30, 45, 60, 75, 90, 105 and 120 minutes after starting the endotoxin or saline infusion. Hypoxanthine and uric acid were determined from arterial and portal venous blood samples taken at baseline, 60 and 120 minutes later. We based our calculation of the quantity of purine compounds produced by the intestine on the difference between portal venous and arterial concentrations.

**Assessment of intestinal permeability and absorption**

Timed recovery of 3-O-methyl-D-glucose, lactulose and L-rhamnose in urine after duodenal administration was assessed in our endotoxaemic rats in order to estimate absorptive capacity and intestinal permeability. In brief, after the animals were prepared as described above and the LPS infusion was started, the rats received 3 ml of a solution containing 25 g/l 3-O-methyl-D-glucose (Sigma-Aldrich Chemie GmbH, Munich, Germany), 25 g/l lactulose (Sigma-Aldrich Chemie GmbH, Munich, Germany) and 10 g/l L-rhamnose (Sigma-Aldrich Chemie GmbH, Munich, Germany) direct into the duodenum after puncturing the proximal part of the organ. Urine was collected after animals were euthased by puncturing the urinary bladder. High performance HPLC was conducted according to the procedure described by Sorensen and colleagues [29]. Preabsorption factors, such as dilution by secretion and intestinal transit time, and postabsorption factors, such as systemic distribution and renal clearance, are assumed to affect the saccharides equally. Therefore, the urinary excretion rhamnose/glucose and lactulose/rhamnose ratios are considered as parameters for intestinal absorption capacity and permeability, respectively [29,30].
Evaluation of intestinal mucosal damage

After the animals were sacrificed, segments of the distal ileum 3 to 5 cm in length were cautiously exteriorised and immediately snap frozen in liquid nitrogen. The frozen ileal mucosa samples were cut into 4 μm thick sections using a cryostat (Leica CM1850, Leica Microsystems, Wetzlar, Germany), then mounted on super frost slides, air dried at 37°C, overnight and stained with haematoxylin and eosin following standard procedures. Mucosal damage grading was assessed by two independent observers according to the procedures described by Chiu and colleagues [31] (Tab. 1).

Caecal ligation and puncture

Caecal ligation and puncture (CLP) was performed as described previously [32-36]. In brief, female C57BL/6 mice aged 12 to 16 weeks were anaesthetised by intraperitoneal administration of 75 mg/kg Ketamine (Ketanest, Pfizer Pharma, Karlsruhe, Germany) and 16 mg/kg Xylazine (Rompun, Bayer AG, Leverkusen, Germany) in 0.2 ml sterile pyrogen-free saline (Braun AG, Melsungen, Germany). The caecum was exposed through a 1.0 to 1.5 cm abdominal mid-line incision and subjected to a ligation 6 mm from the caecal tip followed by a single puncture with a G23 needle. A small amount of stool was expelled from the punctures to ensure patency. The caecum was returned into the peritoneal cavity and the abdominal incision was closed by layers with 5/0 prolene thread (Ethicon, Norderstedt, Germany). No antibiotics were administered in this model. For the sham-operated mice serving as controls, the caecum was mobilised but no ligation or puncture was performed.

In order to investigate the therapeutic effect of EHNA, 10 mg/kg of the adenosine deaminase inhibitor was administered by intraperitoneal injection after 0, 12 and 24 hours or 4, 12 and 24 hours. Control groups received the same volume of LPS-free 0.9% NaCl solution. CLP was performed blind with respect to the identity of the treatment group. Survival after CLP was assessed four to six times a day for seven days.

Statistical analysis

Data were analysed using the R language and environment for statistical computing and graphics (version 2.7.2) [37]. Data are presented in one dimensional dot plots, as well as mean and standard error of the mean (SEM) or using Kaplan-Meier survival curves. We performed Bartlett’s test for homogeneity of variances. The differences between groups were assessed by one-way analysis of variance (ANOVA), post hoc Tukey-Kramer method for pairwise comparisons and log-rank-test for survival curve analysis. p < 0.05 were considered significant.

Results

Purine compounds

At the beginning of the experiment, mean arterial pressure and temperature showed no differences between groups and remained stable throughout the observation period in all groups (Table 2). The haemodynamic parameters of experimental animals are shown in Table 3.

Bartlett’s test for all experimental groups revealed homogeneity of variances. In the control animals, the intestinal hypoxanthine and uric acid production remained statistically unchanged throughout the observation period (one-way ANOVA: hypoxanthine p = 0.6, uric acid p = 0.6). Similarly, the intestinal hypoxanthine and uric acid production in endotoxin-stimulated animals with EHNA application (LPS + EHNA group) did not change during the duration of the experiment (one-way ANOVA: hypoxanthine p = 0.07, uric acid p = 0.9). In contrast, in the endotoxaemic rats without EHNA application (LPS group), the intestinal production of hypoxanthine increased from 9.8 ± 90.2 μmol/l at baseline to 411.4 ± 124.6 μmol/l after 120 minutes (post hoc Tukey-Kramer test: p = 0.03), and the intestinal production of uric acid increased from 1.5 ± 2.3 mmol/l at baseline to 13.1 ± 2.7 mmol/l after 120 minute (post hoc Tukey-Kramer test: p = 0.01). Furthermore, after 120 minutes the LPS group differed in the mean of intestinal hypoxanthine and uric acid production from control and EHNA treated animals (hypoxanthine production: ANOVA p = 0.02, post hoc Tukey-Kramer test p = 0.03; uric acid produc-

Table 1

| Grade | Histological characteristics                                      |
|-------|------------------------------------------------------------------|
| Grade 0 | Normal mucosal villi                                           |
| Grade 1 | Subepithelial Gruenhagen’s space (oedema), usually at the apex of the villus |
| Grade 2 | Extension of the subepithelial space with moderate lifting of epithelial layer from the lamina propria |
| Grade 3 | Massive epithelial lifting down the sides of villi. A few tips may be denuded |
| Grade 4 | Denuded villi with lamina propria and dilated capillaries exposed |
| Grade 5 | Digestion and disintegration of lamina propria; haemorrhage and ulceration |
Intestinal permeability and absorption capacity
The recovery of saccharides excreted in urine at their appropriate ratios is shown in Figure 3. The lactulose/L-rhamnose ratio of the LPS group with an elevation of about three times the value of the control group (ANOVA $p = 3.5 \times 10^{-9}$, Tukey-Kramer test $p = 2 \times 10^{-7}$) reflects a highly permeable small intestine in septic rats. Through the application of EHNA, intestinal permeability could be recovered to a value comparable with that of control animals (Figure 3a). Also, the LPS animals had decreased L-rhamnose/3-O-methyl-D-glucose urine excretion ratios (0.38 ± 0.05) compared with normal controls (0.58 ± 0.12, post hoc test $p = 0.05$), consistent with a decrease in gastrointestinal functional absorptive capacity. ADA1 inhibition by a single dose of EHNA diminished this effect (Figure 3b).

Evaluation of intestinal mucosal damage
Histologically, we were able to demonstrate a protective effect of ADA1 inhibition by EHNA against intestinal mucosal damage in our endotoxaemic animal model (Figures 4 and 5). According to an established mucosal damage score [31], the control and therapy groups (LPS + EHNA) are not statistically different even though the score is somewhat increased in the therapy group. In contrast, the mucosa damage score of the septic animals is higher compared with control and therapy animals ($p < 0.05$).

Survival after CLP
Septic shock induction by CLP resulted in a 160-hour survival rate of about 25%. In comparison, the direct adenosine deaminase-1 inhibition after septic shock induction via CLP resulted in a 160-hour survival rate of about 75% ($p = 0.0018$). A protective effect was still present when the treatment of EHNA was delayed for four hours after CLP (55% survival, $p = 0.029$). Kaplan-Meier survival curves are shown in Figure 6.

Discussion
Adenosine and its receptors play a crucial role in the regulation of inflammatory responses and in limiting inflammatory tissue destruction [4-6]. Elevation of adenosine and activation of its receptors and their downstream signalling are promising targets for treatment of septic conditions [38]. Thiel and colleagues showed that intravenous infusion of adenosine during endotoxaemia protects from oxygen-mediated tissue injury without compromising the bactericidal mechanisms of polymorphonuclear leucocytes [39]. In further studies, the authors demonstrate that the $A_2A$ receptor agonist compensated for the loss of endogenously formed adenosine in inflamed lungs of oxygenated mice and thereby prevented inflammatory lung injury and death [40]. The inhibition of the degradation of adenosine by ADA improves survival from sepsis [19-21]. ADA activity is composed of the two isoenzymes ADA1 and ADA2 [22]. ADA2 coexists with ADA1 only in monocytes and macrophages [23]. The specific ADA2 inhibitor 2'-deoxycoformycin (pentostatin), primarily used to treat hairy cell leukaemia, has seen increasing attention as an immunosuppressant [41]. Law and colleagues demonstrated the beneficial effect of pentostatin application in preventing the systemic inflammatory response syndrome secondary to faecal peritonitis in rats [24]. On the other hand, ADA1 is ubiquitous and highly efficient in deaminating the substrates adenosine and 2’deoxyadenosine.

In addition, a hallmark of septic conditions are their intestinal barrier dysfunctions resulting in bacterial translocation and thereby perpetuating and aggravating the syndrome [25,26]. Endothelial cells are important mediators in orchestrating the host response in sepsis [42]. A pivotal feature of sepsis is microvascular dysfunction in which endothelial activation, dysfunction and thereby hyperpermeability seem to play a central
role [43]. Endothelial hyperpermeability results in a vascular leakage of the intestinal mucosa that might contribute to increased gut permeability. Suttorp and Seybold identified the importance of cyclic guanosine monophosphate-stimulated PDE2 for the integrity of the endothelial barrier function [27,28]. They presented evidence that in severe infection, high PDE2 activity may contribute to endothelial barrier dysfunction, which can be antagonised by PDE2 inhibition [28].

We based our approach on the hypothesis that ADA1 and PDE2 inhibition, targeting monocytes and the endothelium/intestinal epithelium respectively, could be beneficial in experimental septic conditions and employed EHNA, a specific ADA1 and PDE2 inhibitor, as the therapeutic agent.

There are numerous animal models and all of them have limitations and advantages. Indeed there is controversy whether endotoxaemic shock and sepsis are different entities or not. However, the LPS model has a role in helping to understand the sepsis phenotype [44]. As our experimental basis, we utilised this commonly used endotoxicosis model. LPS-induced endotoxaemic shock simplifies aspects of experimental design while maintaining features of a compensated human sepsis (such as hypermetabolism, anorexia, mild hypotension, leucocytosis and hyperlactataemia [45,46]). Furthermore doses of LPS are readily measured and controlled because it is a stable and relatively pure compound. This ensures reproducibility of the septic challenge. As shown by Schmidt and colleagues, this endotoxaemic rat model is associated with a release of purine metabolites from the intestinal tract during endotoxaemia [47]. In our endotoxaemic rats, the intestinal production of hypoxanthine and uric acid was also increased. In contrast, in endotoxaemic animals treated with the ADA1/PDE2 inhibitor EHNA, an increased intestinal production was not observed.

### Table 3

| Parameter | Group          | Time (minutes) |
|-----------|----------------|----------------|
|           | 0              | 60             | 120            |
| art. SO₂  | Control        | 94.5 ± 0.7     | 97.2 ± 0.5     | 95.5 ± 1.0 |
|           | LPS            | 96.3 ± 0.8     | 97.4 ± 0.5     | 97.2 ± 0.3 |
|           | LPS + EHNA     | 94.4 ± 0.5     | 92.4 ± 4.3     | 91.3 ± 5.6 |
| art. PO₂  | control        | 83.4 ± 4.4     | 86.7 ± 3.7     | 88.3 ± 2.8 |
|           | LPS            | 95.1 ± 9.5     | 107.1 ± 9.4    | 99.7 ± 4.2 |
|           | LPS + EHNA     | 75.7 ± 2.3     | 89.5 ± 5.3     | 86.6 ± 6.9 |
| art. PCO₂ | control        | 47.2 ± 1.4     | 41.3 ± 1.7     | 40.2 ± 1.1 |
|           | LPS            | 42.8 ± 1.6     | 37.1 ± 1.1     | 35.0 ± 0.8 |
|           | LPS + EHNA     | 49.5 ± 1       | 35.8 ± 3.9     | 34.0 ± 2.4 |
| art. HCO₃⁻| control        | 26.9 ± 0.5     | 24.5 ± 1.0     | 24.1 ± 0.5 |
|           | LPS            | 25.3 ± 1.0     | 22.8 ± 0.6     | 18.6 ± 1.0 |
|           | LPS + EHNA     | 28.2 ± 0.5     | 21.3 ± 3.4     | 18.7 ± 2.5 |
| art. PH   | control        | 7.37 ± 0.01    | 7.40 ± 0.01    | 7.39 ± 0.01 |
|           | LPS            | 7.38 ± 0.01    | 7.40 ± 0.01    | 7.35 ± 0.02 |
|           | LPS + EHNA     | 7.36 ± 0.01    | 7.28 ± 0.12    | 7.31 ± 0.07 |
| art. BE   | control        | 1.4 ± 0.6      | 0.2 ± 1.0      | 0.2 ± 0.4 |
|           | LPS            | 0.5 ± 0.9      | -1.1 ± 0.7     | -5.8 ± 1.3 |
|           | LPS + EHNA     | 2.4 ± 0.6      | -5.3 ± 5.9     | -6.6 ± 3.7 |
neither for hypoxanthine or uric acid. Increased serum uric acid correlates with severe sepsis and septic shock [48]. In addition, serum uric acid levels correlated significantly with scores from Acute Physiology and Chronic Health Evaluation (APACHE) II in critically ill patients [49,50]. Uric acid is a principal endogenous danger signal and is released from injured
cells. Shi and colleagues demonstrated that by eliminating uric acid the immune response to antigens associated with injured cells is inhibited [51].

The data of Johnston and van Nieuwenhoven demonstrated that patients with acute sepsis exhibit an increased intestinal permeability (lactulose/rhamnose urinary excretion ratio) and a decreased intestinal absorption capacity (rhamnose/glucose urinary excretion ratio) compared with healthy control subjects [52,53]. In our study, the values for intestinal permeability and absorption capacity as a measure of an epithelial dysfunction of endotoxaemic animals treated with EHNA were comparable with the control rats. In contrast, the endotoxaemic animals presented a disturbed intestinal permeability and absorption capacity. Our assumption that the stabilisation of the intestinal barrier might be the result of endothelial hyperpermeability alteration by PDE2 inhibition is highly speculative and has to be confirmed by further functional studies.

The morphological correlate to disturbed intestinal permeability and absorption capacity in septic patients is a modified and destroyed intestinal mucosal architecture that is quantifiable by intestinal mucosal damage grading according to Chiu and colleagues [31]. By this means, we were able to demonstrate a significantly better outcome for animals treated with the ADA1/PDE2 inhibitor.

At this point we employed the well established more complex animal model of sepsis (caecal ligation after puncture) with an elevated number of individuals (n = 84) to strengthen the statement that EHNA could have beneficial effects in experimental septic conditions. Both LPS and CLP models had similar mortality rates. The data give further evidence of a survival benefit even when treatment was delayed for four hours, which is more realistic in the clinical routine and suggestive of a therapeutic potential of EHNA for treating septic conditions.

**Conclusion**

In this study based on a septic animal model, we present further evidence of the beneficial effects of administering the ADA1 and PDE2 inhibitor EHNA. This effect is detectable even when EHNA is applied four hours after sepsis induction. It may therefore be a potential therapeutic option in the treatment of septic conditions – still one of medicine’s big challenges.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

NK carried out animal experiments and participated in the study design; BF participated in the design of the study, per-
formed statistical analysis, drafted and wrote the manuscript, and prepared the figures. NK and BF contributed equal shares to this project. HW carried out animal experiments. SH and HS participated in the design of the study. HB participated in the design of the study especially the HPLC intestinal permeability experiments. CV participated in the design and co-ordination of the study. MW conceived the study idea, participated in its design and co-ordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by grants from the University of Heidelberg. We would like to thank Roland Galmbacher and Angelika Brüntings for their expert technical assistance. Dr Sebastian Aulmann and Dr Stefan Macher-Goeppinger are gratefully acknowledged for their statistical support. We are also grateful to Susanne Thurm for professional assistance in preparing the manuscript.

References
1. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990, 113:227-242.
2. Hynes-Gay P, Lalla P, Leo M, Merrill-Bell A, Nicholson M, Villanuel E: Understanding sepsis: from SIRS to septic shock. Dynamics 2002, 13:17-20; 22–24; quiz 25–26
3. Martin C, Leone M, Viviani X, Ayem ML, Guieu R: High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000, 28:3198-3202.
4. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M: Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004, 173:21-24.
5. Ohta A, Sitkovsky M: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920.
6. Sullivan GW, Fang G, Linden J, Scheld WM: A2A adenosine receptor activation improves survival in mouse models of endotoxia and sepsis. J Infect Dis 2004, 189:1897-1904.
7. Heller AR, Rothermel J, Weigand MA, Plaschke K, Schmeck J, Wendel M, Bardenheuer HJ, Koch T: Adenosine A1 and A2 receptor agonists reduce endotoxin-induced cellular energy depletion and oedema formation in the lung. Eur J Anaesthesiol 2007, 24:258-266.
8. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004, 22:657-682.
9. Fredholm BB: Purines and neutrophil leukocytes. Gen Pharmacol 1997, 28:345-350.
10. Murphee LJ, Sullivan GW, Marshall MA, Linden J: Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. Biochem J 2005, 391:575-580.
11. Lappas CM, Rieger JM, Linden J: A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005, 174:1079-1089.

Figure 6
Adenosine deaminase 1 inhibition protects against septic shock induced by caecal ligation and puncture (CLP). Kaplan-Meier survival curves; septic shock induction by CLP resulted in a 160-hour survival rate of about 25%. In contrast, direct adenosine deaminase-1 inhibition after septic shock induction via CLP resulted in a 160-hour survival rate of about 75% (p = 0.0018). A protective effect was still present when the erythro-9-[2-hydroxyl-3-nonyl] adenine (EHNA) treatment was delayed for four hours after CLP (56% survival, p = 0.029).

Key messages
EHNA treatment after experimental endotoxemia/sepsis induction results in:
- Attenuated intestinal production of hypoxanthine (indicator of cellular energy failure);
- Decreased intestinal lactulose/L-rhamnose ratio (measure of intestinal permeability);
- Normal mucosal histology of the terminal ileum compared with an appropriate control group;
- Improved survival rate in CLP mice even when EHNA treatment was delayed for four hours.
12. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV: Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol 1999, 55:614-624.

13. Varani K, Gessi S, Dalpiaz A, Borea PA: Pharmacological and biochemical characterization of purified A2A adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol 1996, 117:1693-1701.

14. Sitkovsky MV: Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochim Biophys Acta 2003, 1649:5-91.

15. Cronstein BN, Levin RI, Belknap J, Weissmann G, Hirschhorn R: Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986, 78:760-770.

16. Eltzschig HK, Iba JA, Furuta GT, Leonard MO, Jacobson KA, Eny-Jink J, Robinson SC, Colgan SP: Coordinated adenine nucleotide- phosphorodiesterase and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003, 198:783-796.

17. Thiel M, Chambers JD, Chouker A, Fischer S, Zourelidou C, Dombrowski P, Alarcon K: Effect of adenosine on the expression of beta(2) integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J Leukoc Biol 1996, 59:671-682.

18. Fierstuen GS, Doyle B, Bullough DA, Gruber HE, Sagaji FG, Mon WS, Sanborn KB, Mullan KM: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994, 152:5853-5859.

19. Adanin S, Yalovetsky IV, Nardulli BA, Sam AD 2nd, Jon ves ZS, Law WR: Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am J Physiol Regul Integr Comp Physiol 2002, 282.R1324-1332.

20. Cohen ES, Law WR, Easington CR, Cruz KG, Nardulli BA, Balk RA, Pilliro JL, Hellenberg SM: Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am J Respir Crit Care Med 2002, 166:16-20.

21. Lee HT, Kim M, Joo JD, Gallos G, Chen JF, Emala CW: A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006, 291:R959-969.

22. Gakis C: Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J 1996, 9:632-633.

23. Conlon BA, Law WR: Macrophages are a source of extracel lular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol 2004, 138:14-20.

24. Law WR, Vail VE, Conlon BA: Therapeutic potential for tran sient inhibition of adenosine deaminase in systemic inflammatory response syndrome. Crit Care Med 2003, 31:1475-1481.

25. Fink MP: Effect of critical illness on microbial translocation and gastrointestinal mucosa permeability. Semin Respir Infect 1994, 9:256-260.

26. Fink MP: Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med 1991, 19:567-641.

27. Suttorp N, Etcreizer P, Hinpenstiel S, Fuhrmann M, Krull M, Tenor H, Schudt C, Wente MN, Encke J, Werner J, Dalpke AH, Streum mel W, Nawroth PP, Martin E, Krammer PH, Bierhaus A, Weigand MA: Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med 2008, 36:404-408.

28. Bouchon A, Panchetti F, Weigand MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.

29. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.

30. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery after experimental peritonitis. J Immunol 1999:3762-3766.

31. Liensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kuschers FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling GG, Nawroth PP, Arnold B: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 114:1641-1650.

32. A Language and Environment for Statistical Computing [http://www.R-project.org]

33. Hasko G, Pacher P: A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008, 83:447-455.

34. Thiel M, Holzer K, Kreimeier U, Moritz S, Peter K, Messmer K: Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Shock 2001, 15:49-55.

35. Schouten M, Wiersinga WJ, Levi M, Poll T van der: Inflammatory response syndrome in endotoxemia and sepsis. J Clin Invest 2003, 112:135-145.

36. Levi M, Poll T van der: Inflammatory response syndrome: a dynamic, and metabolic reappraisal. Arch Surg 1970, 101:478-483.

37. Hofer S, Eisenbach C, Luik IC, Schneider L, Bode K, Brueckmann M, Mautner S, Wente MN, Encke J, Werner J, Dalpke AH, Streumel W, Nawroth PP, Martin E, Krammer PH, Bierhaus A, Weigand MA: Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med 2008, 36:404-408.

38. Bouchon A, Panchetti F, Weigand MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.

39. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170.

40. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery after experimental peritonitis. J Immunol 1999:3762-3766.

41. Liensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kuschers FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling GG, Nawroth PP, Arnold B: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 114:1641-1650.

42. Higman M, Vogelsang GB, Chen A: Pentostatin – pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother 2004, 5:2605-2613.

43. Schouten M, Wiersinga WJ, Levi M, Poll T van der: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008, 83:447-455.

44. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P: Experimental models of sepsis and their clinical relevance. Shock 2000, 13:365-375.

45. Hasko G, Pacher P: A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008, 83:447-455.

46. Fink MP, Heard SO: Laboratory models of sepsis and septic shock. J Surg Res 1999, 87:1-9.

47. Fish RE, Lang CH, Spitzer JA: Regional blood flow during continuous low-dose endotoxin infusion. Circ Shock 1986, 18:267-275.

48. Schmidt H, Weigand MA, Schmidt W, Plaschke K, Martin E, Bardenheuer HJ: Effect of dopaminergic antidepressant treatment on intestinal tissue concentrations of high-energy phosphates and intestinal release of purine compounds in endotoxic rats. Crit Care Med 2000, 28:1979-1984.

49. Batra S, Kumar R, Seema, Kapoor AK, Ray G: Alterations in antioxidant status during neonatal sepsis. Ann Trop Paediatr 2000, 20:27-33.

50. Chuang CC, Shiesh SC, Chi CH, Tu YF, Hsu LR, Shieh CC, Chen MF: Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis. Crit Care Med 2006, 10.R38.

51. Jabb CN, Sigurdsson GH, Neglen P: Plasma levels of highenergy compounds compared with severity of illness in critically ill patients in the intensive care unit. Surgery 1998, 124:65-72.

52. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.

53. Johnston JD, Harvey CJ, Menzies IS, Treacher DF: Gastrointestinal permeability and absorptive capacity in sepsis. Crit Care Med 1996, 24:1144-1149.
53. van Nieuwenhoven MA, Geerling BJ, Deutz NE, Brouns F, Brummer RJ: The sensitivity of the lactulose/rhamnose gut permeability test. *Eur J Clin Invest* 1999, 29:160-165.